The role of p38 mitogen-activated protein kinase in serum-induced leukemia inhibitory factor secretion by bone marrow stromal cells from pediatric myelodysplastic syndromes

Leukemia Research
Simone V da CostaM Mitzi Brentani

Abstract

Stromal cells from pediatric myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) associated with MDS (MDS-AML) present high expression of leukemia inhibitor factor (LIF). We demonstrated using mitogen-activated protein kinase (MAPK) inhibitors that in stromal cells from pediatric MDS and MDS-AML, p38MAPK was critical in serum-induced secretion of LIF. The serum induction of phosphorylated p38MAPK form was observed only in stromal cells from healthy children, whereas in MDS and MDS-AML basal levels were maintained suggesting constitutive p38MAPK activation. Our study suggested the possible importance in pediatric MDS of p38MAPK signaling pathway which may be a future therapeutic target.

References

Mar 26, 1998·Cytokine·F RougierY Denizot
Feb 11, 2005·The New England Journal of Medicine·Mario Cazzola, Luca Malcovati
Nov 10, 2006·Leukemia Research·Rosimeire A RoelaM Mitzi Brentani
Mar 10, 2007·Current Medicinal Chemistry·Armin ZebischJakob Troppmair

❮ Previous
Next ❯

Citations

Jan 6, 2012·International Journal of Hematology·Marc H G P Raaijmakers
Jun 19, 2012·The Biochemical Journal·Feride Oeztuerk-Winder, Juan-Jose Ventura
Feb 11, 2015·Cellular and Molecular Life Sciences : CMLS·Lili YangSheng Wei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.